Who Buys Aminophylline from India — 249 Importers Behind a $5.9M Market

The analysis of Aminophylline imports from India reveals a diverse buyer landscape, encompassing various segments:

• Distributors: Entities like HEKO PHARMACY LTD (Tanzania) and ZEFARM D.O.O (Serbia) are prominent distributors. They typically procure large volumes to supply regional markets, ensuring consistent availability. Their repeat purchases indicate established supply chains and sustained demand.

• Hospital Groups: While specific hospital groups are not explicitly listed among the top buyers, it's common for such entities to engage in bulk purchasing to meet patient needs. They often participate in tenders and require reliable suppliers to maintain uninterrupted treatment regimens.

• Retail Chains: Buyers like NKOYO CHEMISTS (Nigeria) represent retail pharmacy chains. These entities focus on stocking essential medications for direct consumer sales, often placing smaller, more frequent orders to manage inventory effectively.

• Government Procurement: Organizations such as M/S PRINCE PHARMA SARL (Congo DR) may be involved in government tenders or supply contracts, aligning with national health initiatives to provide essential medicines. Their purchasing patterns are typically aligned with public health program requirements and budget cycles.

• Re-exporters: Some buyers might function as re-exporters, procuring Aminophylline for distribution to neighboring countries, leveraging logistical advantages and regional demand.

• Contract Manufacturers: While not explicitly identified in the top buyers, contract manufacturers may source Aminophylline as an active pharmaceutical ingredient (API) for formulation into finished products, adhering to specific client requirements and regulatory standards.

The demand for Aminophylline in importing countries is primarily driven by the prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). According to the World Health Organization (WHO), as of 2025, approximately 262 million people globally suffer from asthma, with a significant burden in low- and middle-income countries. Aminophylline, listed on the WHO Essential Medicines List, is a critical bronchodilator used in managing these conditions.

Government healthcare programs and the expansion of universal health coverage have further stimulated demand. Many countries have integrated Aminophylline into their national treatment guidelines and procurement lists, often through tender-based purchasing mechanisms. The presence of 249 buyers across 88 countries, as per TransData Nexus data, underscores the widespread reliance on Aminophylline to meet public health needs. This extensive buyer network presents substantial market opportunities for suppliers, particularly in regions with high disease prevalence and robust government health initiatives.

The analysis of Aminophylline imports from India reveals a diverse buyer landscape, encompassing various segments:

• Distributors: Entities like HEKO PHARMACY LTD (Tanzania) and ZEFARM D.O.O (Serbia) are prominent distributors. They typically procure large volumes to supply regional markets, ensuring consistent availability. Their repeat purchases indicate established supply chains and sustained demand.

• Hospital Groups: While specific hospital groups are not explicitly listed among the top buyers, it's common for such entities to engage in bulk purchasing to meet patient needs. They often participate in tenders and require reliable suppliers to maintain uninterrupted treatment regimens.

• Retail Chains: Buyers like NKOYO CHEMISTS (Nigeria) represent retail pharmacy chains. These entities focus on stocking essential medications for direct consumer sales, often placing smaller, more frequent orders to manage inventory effectively.

• Government Procurement: Organizations such as M/S PRINCE PHARMA SARL (Congo DR) may be involved in government tenders or supply contracts, aligning with national health initiatives to provide essential medicines. Their purchasing patterns are typically aligned with public health program requirements and budget cycles.

• Re-exporters: Some buyers might function as re-exporters, procuring Aminophylline for distribution to neighboring countries, leveraging logistical advantages and regional demand.

• Contract Manufacturers: While not explicitly identified in the top buyers, contract manufacturers may source Aminophylline as an active pharmaceutical ingredient (API) for formulation into finished products, adhering to specific client requirements and regulatory standards.

The demand for Aminophylline in importing countries is primarily driven by the prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). According to the World Health Organization (WHO), as of 2025, approximately 262 million people globally suffer from asthma, with a significant burden in low- and middle-income countries. Aminophylline, listed on the WHO Essential Medicines List, is a critical bronchodilator used in managing these conditions.

Government healthcare programs and the expansion of universal health coverage have further stimulated demand. Many countries have integrated Aminophylline into their national treatment guidelines and procurement lists, often through tender-based purchasing mechanisms. The presence of 249 buyers across 88 countries, as per TransData Nexus data, underscores the widespread reliance on Aminophylline to meet public health needs. This extensive buyer network presents substantial market opportunities for suppliers, particularly in regions with high disease prevalence and robust government health initiatives.